Dongcheng Pharmaceuticl: Plan to spin off subsidiary Lanatse to list on the main board of the Hong Kong Stock Exchange.

Dongcheng Pharmaceutical announced that the company's board of supervisors has approved the proposal to spin off its subsidiary Yantai Lanna Cheng Biotechnology Co., Ltd. to list on the main board of The Stock Exchange of Hong Kong Limited. The initial offering size of Lanna Cheng's listing shall not exceed 25% of the expanded total share capital after the offering, and the lead coordinator is granted the over-allotment option of up to 15% of the initial offering size for H shares. This spin-off listing plan needs to be submitted to the company's shareholders' meeting for approval.